Trial Profile
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2023
Price :
$35
*
At a glance
- Drugs Valanafusp alfa (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions
- Sponsors ArmaGen Technologies
- 19 Feb 2023 Status changed from active, no longer recruiting to completed.
- 03 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Jun 2017.
- 23 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Aug 2017.